PDAC	Pancreatic ductal adenocarcinoma
PC	Pancreatic cancer
DM	Diabetes mellitus
NODM	New-onset diabetes mellitus
T2DM	Type 2 DM
OS	Overall survival
ICD-10	The International Statistical Classification of Diseases and Related Health Problems
CSK	Central Clinical Hospital
MSWiA	Ministry of Interior and Administration
ECOG	Eastern Cooperative Oncology Group performance status
non-DM	Group without diabetes mellitus
OGTT	Oral glucose tolerance test
AJCC	American Joint Cancer Committee
CT	Computed tomography
SD	Standard deviation
HR	Hazard ratio
CRP	C reactive protein
CLR	CRP/lymphocytes ratio
M	Mean
n	Number
MD	Median
95% CI	95% Confidence Interval
DFS	Disease-free survival
PFS	Progression-free survival
CEA	Carcino-embryonic antigen
CA19-9	Carbohydrate antigen 19-9
TNM	TNM Classification of Malignant Tumors
T	Tumour size
N	Lymph nodal involvement
M	Distant metastasis
R	Resection margin
GH/IGF	Growth hormone/insulin-like growth factor
IGF-1	Insulin-like growth factor-1
AGE	Advanced glycation end products
ASCO	American Society of Clinical Oncology
mTOR	The mammalian target of rapamycin
mFOLFIRINOX	A chemotherapy regimen: FOL—folinic acid
F	Fluorouracil (5-FU)
IRIN	Irinotecan
OX	Oxaliplatin
MMP9	Matrix metalloproteinase-9
AMP/ATP	Adenosine monophosphate/adenosine triphosphate
ADP/ATP	Adenosine diphosphate/adenosine triphosphate
AMPK	AMP-activated protein kinase
CAR	CRP/albumin ratio
HDL	High-density lipoproteins